. 2023 Apr 18;10(4):2319–2329. doi: 10.1002/ehf2.14380

Table 4.

Comparison of serial biomarker and imaging parameters in the treatment and treatment‐naïve groups

	Treatment group (n = 85)			Treatment‐naïve group (n = 33)
	Baseline	After 12 months	P value	Baseline	After 12 months	P value
Biomarkers
hs‐cTnT, ng/mL	0.054 (0.036–0.082) ^a	0.044 (0.033–0.076) ^a	0.002	0.050 (0.036–0.082) ^b	0.068 (0.051–0.081) ^b	0.15
BNP, pg/mL	210 (114–295)	175 (120–306)	0.59	329 (223–486)	329 (168–546)	0.68
eGFR, mL/min/1.73 m²	53.0 ± 13.8	50.4 ± 14.5	0.001	47.8 ± 13.9	41.3 ± 15.1	0.004
Echocardiogram parameters
LVDd, mm	41.3 ± 5.0	41.6 ± 5.0	0.31	43.7 ± 7.3 ^c	42.0 ± 6.8 ^c	0.03
LVDs, mm	32.1 ± 6.2	32.6 ± 6.3	0.20	32.0 ± 7.2 ^c	31.1 ± 6.8 ^c	0.12
IVSd, mm	15.9 ± 2.3	15.7 ± 2.1	0.32	15.3 ± 2.2 ^c	16.2 ± 2.0 ^c	0.04
LVPWd, mm	16.0 ± 2.7	16.2 ± 2.8	0.45	15.3 ± 2.3 ^c	15.9 ± 2.6 ^c	0.16
LVEF, %	50.3 ± 10.6	50.1 ± 10.9	0.78	52.3 ± 9.8 ^c	51.0 ± 10.1 ^c	0.27
LV‐GLS (%)	−8.3 ± 2.7	−8.4 ± 2.8	0.76	−9.8 ± 2.8 ^c	−9.3 ± 2.5 ^c	0.33
Apical LS (%)	−12.3 ± 4.1	−13.0 ± 4.4	0.20	−14.3 ± 4.7 ^c	−12.2 ± 6.2 ^c	0.09
Middle LS (%)	−6.9 ± 3.6	−6.9 ± 2.7	0.95	−8.8 ± 3.0 ^c	−8.7 ± 3.0 ^c	0.90
Basal LS (%)	−4.7 ± 2.7	−4.3 ± 2.9	0.13	−4.7 ± 2.7 ^c	−5.1 ± 2.7 ^c	0.35
CMR parameters
Native T1 value (ms)	1414 ± 54 ^d	1421 ± 64 ^d	0.44	No data	No data
ECV (%)	52.2 ± 11.2 ^d	53.2 ± 11.7 ^d	0.44	No data	No data

Abbreviations: BNP, B‐type natriuretic peptide; CMR, cardiac magnetic resonance imaging; ECV, extracellular volume fraction; eGFR, estimated glomerular filtration rate; hs‐cTnT, high‐sensitivity cardiac troponin T; IVSd, interventricular septum diameter; LS, longitudinal strain; LVDd, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter; LVEF, left ventricular ejection fraction; LV‐GLS, left ventricular global longitudinal strain; LVPWd, left ventricular posterior wall diameter.

^{^a}

n = 81.

^{^b}

n = 19.

^{^c}

n = 31.

^{^d}

n = 15.